Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.
Identifieur interne : 000210 ( Main/Exploration ); précédent : 000209; suivant : 000211Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.
Auteurs : Christopher J. Morabito [Autriche] ; Bagirath Gangadharan [Autriche]Source :
- Clinical and translational science [ 1752-8062 ] ; 2020.
Abstract
Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases.
DOI: 10.1111/cts.12816
PubMed: 32420691
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000006
- to stream PubMed, to step Curation: 000006
- to stream PubMed, to step Checkpoint: 000059
- to stream Ncbi, to step Merge: 002122
- to stream Ncbi, to step Curation: 002122
- to stream Ncbi, to step Checkpoint: 002122
- to stream Main, to step Merge: 000208
- to stream Main, to step Curation: 000210
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.</title><author><name sortKey="Morabito, Christopher J" sort="Morabito, Christopher J" uniqKey="Morabito C" first="Christopher J" last="Morabito">Christopher J. Morabito</name><affiliation wicri:level="1"><nlm:affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Gangadharan, Bagirath" sort="Gangadharan, Bagirath" uniqKey="Gangadharan B" first="Bagirath" last="Gangadharan">Bagirath Gangadharan</name><affiliation wicri:level="1"><nlm:affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32420691</idno><idno type="pmid">32420691</idno><idno type="doi">10.1111/cts.12816</idno><idno type="wicri:Area/PubMed/Corpus">000006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000006</idno><idno type="wicri:Area/PubMed/Curation">000006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000006</idno><idno type="wicri:Area/PubMed/Checkpoint">000059</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000059</idno><idno type="wicri:Area/Ncbi/Merge">002122</idno><idno type="wicri:Area/Ncbi/Curation">002122</idno><idno type="wicri:Area/Ncbi/Checkpoint">002122</idno><idno type="wicri:Area/Main/Merge">000208</idno><idno type="wicri:Area/Main/Curation">000210</idno><idno type="wicri:Area/Main/Exploration">000210</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.</title><author><name sortKey="Morabito, Christopher J" sort="Morabito, Christopher J" uniqKey="Morabito C" first="Christopher J" last="Morabito">Christopher J. Morabito</name><affiliation wicri:level="1"><nlm:affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Gangadharan, Bagirath" sort="Gangadharan, Bagirath" uniqKey="Gangadharan B" first="Bagirath" last="Gangadharan">Bagirath Gangadharan</name><affiliation wicri:level="1"><nlm:affiliation>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Takeda Pharmaceuticals, Massachusetts and Vienna, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical and translational science</title><idno type="eISSN">1752-8062</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases.</div></front></TEI><affiliations><list><country><li>Autriche</li></country></list><tree><country name="Autriche"><noRegion><name sortKey="Morabito, Christopher J" sort="Morabito, Christopher J" uniqKey="Morabito C" first="Christopher J" last="Morabito">Christopher J. Morabito</name></noRegion><name sortKey="Gangadharan, Bagirath" sort="Gangadharan, Bagirath" uniqKey="Gangadharan B" first="Bagirath" last="Gangadharan">Bagirath Gangadharan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000210 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000210 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32420691
|texte= Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32420691" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |